Table 4.
Relative sensitivity and specificity of urine pellet and supernatant for bladder cancer diagnosis, as compared to full void. New cut-offs were determined for urine pellet and supernatant; optimal cut-offs from our previous study were used for full void [6].
| Markers | Pellet | Supernatant | ||
|---|---|---|---|---|
| Relative Sens: Pellet vs. Full Void (95% CI) | Relative Spec: Pellet vs. Full Void (95% CI) | Relative Sens: Supernatant vs. Full Void (95% CI) | Relative Spec: Supernatant vs. Full Void (95% CI) | |
| FAM19A4 | 1.00 * | 1.00 * | 1.00 * | 1.00 * |
| GHSR | 1.60 (0.94–2.74) | 1.00 * | 1.40 (0.88–2.24) | 1.00 * |
| MAL | 1.50 (0.95–2.38) | 0.92 (0.77–1.09) | 1.17 (0.86–1.58) | 1.00 * |
| miR-129 | 1.75 (0.92–3.32) | 1.00 * | 1.50 (0.85–2.64) | 1.00 * |
| miR-935 | 2.67 (1.09–6.52) | 0.92 (0.77–1.09) | 1.33 (0.76–2.35) | 1.00 * |
| PHACTR3 | 1.50 (0.85–2.64) | 0.83 (0.65–1.07) | 1.50 (0.85–2.64) | 0.92 (0.77–1.09) |
| PRDM14 | 1.33 (0.89–1.99) | 1.00 * | 1.00 * | 1.00 * |
| SST | 1.00 * | 1.00 * | 1.50 (0.95–2.38) | 0.83 (0.65–1.07) |
| ZIC1 | 1.00 * | 1.00 * | 1.00 * | 1.00 * |
| Panel GHSR/MAL | 1.43 (0.95–2.14) | 0.92 (0.77–1.09) | 1.00 * | 1.00 * |
* CI not estimable, since there was a perfect match in positive and negative outcomes between both fractions. Abbreviations: CI, confidence interval.